Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:

interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC

clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
Clinical Trials Information System (CTIS).

The EU Clinical Trials Register currently displays 44346 clinical trials with a EudraCT protocol, of which 7374 are clinical trials conducted with subjects less than 18 years old. The register also displays information on 18700 older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).

Examples: Cancer AND drug name. Pneumonia AND sponsor name.
How to search [pdf]

Advanced Search:

Search tools

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Trials with a EudraCT protocol (44,346)
Paediatric studies in scope of Art45 of the Paediatric Regulation (18,700)

44,346 result(s) found. Displaying page 957 of 2,218.

EudraCT Number: 2017-001164-38	Sponsor Protocol Number: VX15-661-113	Start Date*: 2019-06-27
Sponsor Name:Vertex Pharmaceuticals Incorporated
Full Title: A Phase 3, Open-label Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of VX-661 in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous...
Medical condition: Cystic Fibrosis (CF)
Disease:
Population Age: Children, Under 18		Gender: Male, Female
Trial protocol: Outside EU/EEA
Trial results: View results

EudraCT Number: 2017-001428-23

Sponsor Protocol Number: M17GEL

Start Date*: 2017-09-29

Sponsor Name:NKI-AVL

Full Title: AssessinG Efficacy of carboplatin and ATezOlizumab in metastatic Lobular breast cancer: GELATO-trial

Medical condition: breast cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004864	10024745	Lobular breast carcinoma invasive	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: NL (Ongoing)

Trial results: (No results available)

EudraCT Number: 2016-000424-25

Sponsor Protocol Number: 1508175

Start Date*: 2016-04-12

Sponsor Name:CHU Saint-Etienne

Full Title: Low-molecular-weight heparin in constituted vascular intrauterine growth restriction. Randomized multicenter trial

Medical condition: Intrauterine growth restriction (IUGR)

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004868	10022819	Intrauterine growth retardation	LLT
	20.0	100000004868	10048489	Intrauterine growth retard	LLT
	20.0	100000004868	10048488	Growth intrauterine retard	LLT

Population Age: Adults

Gender: Female

Trial protocol: FR (Completed)

Trial results: (No results available)

EudraCT Number: 2018-003714-40

Sponsor Protocol Number: IRONPAD

Start Date*: 2019-04-04

Sponsor Name:Servicio de Angiología y Cirugía Vascular del Hospital Universitario Cruces

Full Title: IMPACT OF INTRAVENOUS IRON TREATMENT OF PREOPERATIVE ANEMIA IN PATIENTS WITH LOWER EXTREMITY PERIPHERAL ARTERY DISEASE

Medical condition: Anemia in patients with chronic lower limb ischemia

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004851	10002272	Anemia	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2015-002571-24	Sponsor Protocol Number: 15/0118	Start Date*: 2016-10-14
Sponsor Name:Joint Research Office
Full Title: A Phase IIA Prospective, Single-Centre, Open Label Clinical Trial to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of Ambroxol in Patients with Parkinson Disease: Ambroxol in Diseas...
Medical condition: Parkinson disease
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: GB (Completed)
Trial results: View results

EudraCT Number: 2018-002155-15

Sponsor Protocol Number: GEICO78-C

Start Date*: 2019-05-16

Sponsor Name:Grupo Español de Investigación en Cáncer de Ovario (GEICO)

Full Title: A randomized, open label, phase II trial of Anti-PD1, TSR-042, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation

Medical condition: Cervical cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004864	10008229	Cervical cancer	LLT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2019-000898-23

Sponsor Protocol Number: 2019/KEP/218

Start Date*: 2019-08-01

Sponsor Name:London School of Hygiene and Tropical Medicine

Full Title: Pharmacokinetics of intramuscular tranexamic acid in trauma patients: a clinical trial

Medical condition: Traumatic haemorrhage

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10022117 - Injury, poisoning and procedural complications	10053476	Traumatic haemorrhage	PT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Completed)

Trial results: View results

EudraCT Number: 2018-001590-24

Sponsor Protocol Number: 01.01.18

Start Date*: 2019-03-21

Sponsor Name:University of Dundee [...]

Full Title: A Trial of the Safety, Tolerability and Efficacy of 2 doses of Cayston (Aztreonam Lysine) compared to placebo in participants with bronchiectasis.

Medical condition: Bronchiectasis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.1	10038738 - Respiratory, thoracic and mediastinal disorders	10006445	Bronchiectasis	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: GB (Temporarily Halted)

Trial results: (No results available)

EudraCT Number: 2016-000847-16

Sponsor Protocol Number: D1532C00057

Start Date*: 2019-01-29

Sponsor Name:National Cancer Institute, Cancer Therapy Evaluation Program

Full Title: A Phase 1/2 Study of the Mitogen Activated Protein Kinase Kinase(MEK) 1 Inhibitor Selumetinib (AZD6244, ARRY-142886, Hydrogen Sulfate) in Children With Neurofibromatosis Type 1 (NF1) and Inoperable...

Medical condition: Neurofibromatosis type 1 (NF1)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10029267	Neurofibroma	PT

Population Age: Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: Outside EU/EEA

Trial results: (No results available)

EudraCT Number: 2016-004997-16

Sponsor Protocol Number: R668-AD-1652

Start Date*: 2018-02-09

Sponsor Name:Regeneron Pharmaceuticals, Inc.

Full Title: A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of dupilumab administered concomitantly with topical corticosteroids in patients, ≥6 years to <12 years o...

Medical condition: Atopic Dermatitis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004858	10003639	Atopic dermatitis	LLT

Population Age: Children, Under 18

Gender: Male, Female

Trial protocol: CZ (Completed) DE (Completed) GB (Completed) PL (Completed)

Trial results: View results

EudraCT Number: 2013-004101-75

Sponsor Protocol Number: S56122-ML10190

Start Date*: 2014-03-28

Sponsor Name:UZ Leuven

Full Title: Randomized crossover trial to assess the effects and quality of life in patients with locally advanced or metastatic pancreatic cancer treated with gemcitabine in combination with nab-paclitaxel: Q...

Medical condition: locally advanced or metastatic pancreatic cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	20.0	100000004864	10033606	Pancreatic cancer non-resectable	LLT
	20.0	100000004864	10033605	Pancreatic cancer metastatic	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: BE (Completed)

Trial results: View results

EudraCT Number: 2018-004348-47

Sponsor Protocol Number: SOGUG-2017-A-IEC(VEJ)-4

Start Date*: 2019-07-10

Sponsor Name:Grupo Español de Oncología Genitourinaria (SOGUG)

Full Title: EFFICACY OF ATEZOLIZUMAB CONCURRENT WITH RADIOTHERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER

Medical condition: MUSCLE-INVASIVE BLADDER CANCER

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004864	10022877	Invasive bladder cancer	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Ongoing)

Trial results: (No results available)

EudraCT Number: 2017-000934-77	Sponsor Protocol Number: 4.0	Start Date*: 2018-05-11
Sponsor Name:Medical University of Vienna
Full Title: Target attainment of Cefazolin Continuous Infusion for Antibiotic Prophylaxis in patients undergoing CABG surgery
Medical condition: Patients referred for CABG to the Department of Cardiac Surgery with planned isolated left mammary artery and vein/radial artery grafts preparation will be asked to participate in this trial.
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: AT (Ongoing)
Trial results: (No results available)

EudraCT Number: 2019-000843-29	Sponsor Protocol Number: MS316	Start Date*: 2019-05-31
Sponsor Name:Ipsen Pharma
Full Title: Recombinant Human Growth Hormone (rhGH) and Recombinant Human Insulin-like Growth Factor-1 (rhIGF-1) Combination Therapy in Children with Short Stature Associated with IGF-1 Deficiency: A Six-year,...
Medical condition: Idiopatic Short Stature in prepubertal children associated with low IGF-1 and normal stimulated GH response
Disease:
Population Age: Children, Adolescents, Under 18		Gender: Male, Female
Trial protocol: Outside EU/EEA
Trial results: View results

EudraCT Number: 2017-004160-35	Sponsor Protocol Number: ISR-003	Start Date*: 2018-03-13
Sponsor Name:Immune System Regulation AB (ISR)
Full Title: A prospective, randomised, controlled, parallel arm, open phase IIa study on the efficacy and safety of the GnRH analogue triptorelin for HIV-1 reservoir reduction in HIV-1 infected male adult pati...
Medical condition: HIV-1 infection
Disease:
Population Age: Adults		Gender: Male
Trial protocol: SE (Ongoing) DE (Ongoing)
Trial results: (No results available)

EudraCT Number: 2019-002626-67	Sponsor Protocol Number: ICOMM19	Start Date*: 2020-01-09
Sponsor Name:Institut Català d'Oncologia
Full Title: EFFICACY AND SAFETY OF THE COMBINATION OF BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS
Medical condition: Multiple myeloma
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: ES (Ongoing)
Trial results: (No results available)

EudraCT Number: 2019-001459-38	Sponsor Protocol Number: KTP-004	Start Date*: 2019-12-10
Sponsor Name:Karus Therapeutics Limited
Full Title: A Phase II study of selective HDAC6 inhibition with KA2507 in advanced biliary tract cancer previously treated with standard of care chemotherapy (ABC-11)
Medical condition: Advanced Biliary Tract Cancer
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: GB (Prematurely Ended)
Trial results: (No results available)

EudraCT Number: 2019-004669-41	Sponsor Protocol Number: RG_15-011	Start Date*: 2020-05-11
Sponsor Name:University of Birmingham
Full Title: STAR-TREC: Can we Save the rectum by watchful waiting or TransAnal microsurgery following (chemo)Radiotherapy versus Total mesorectal excision for early REctal Cancer
Medical condition: Early rectal cancer
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: NL (Ongoing)
Trial results: (No results available)

EudraCT Number: 2018-001377-24

Sponsor Protocol Number: 182RA18009

Start Date*: 2018-10-09

Sponsor Name:Chong Kun Dang Pharmaceutical Corporation (CKD)

Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of CKD-506 Administered to Adult Subjects w...

Medical condition: Rheumatoid arthritis (RA)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.0	10028395 - Musculoskeletal and connective tissue disorders	10039073	Rheumatoid arthritis	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: CZ (Completed)

Trial results: View results

EudraCT Number: 2016-002556-24

Sponsor Protocol Number: CLEE011XDE01

Start Date*: 2016-10-14

Sponsor Name:Novartis Pharma GmbH

Full Title: A national phase IIIb, multi-center, open label study for women and men with hormone-receptor positive, HER2-negative locally advanced or metastatic breast cancer treated with ribociclib (LEE011) i...

Medical condition: HR+, HER2- advanced breast cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	21.1	100000004864	10072737	Advanced breast cancer	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed)

Trial results: View results

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

For support, Contact us.

The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

European Medicines Agency © 1995-Mon Jun 30 07:26:33 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA